A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This randomized, multi-center, double-blind, parallel-group, placebo-controlled study will
evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled
symptoms of schizophrenia. Patients, on stable treatment with antipsychotics, will be
randomized to receive daily oral doses of RO4917838 or matching placebo for 52 weeks,
followed by an optional treatment extension for up to 3 years.